Akari Therapeutics
AKTX
7 hedge funds and large institutions have $3.25M invested in Akari Therapeutics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
30% less funds holding
Funds holding: 10 → 7 (-3)
38% less capital invested
Capital invested by funds: $5.25M → $3.25M (-$2M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$366K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$51.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$419K |
| 2 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$86K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$38K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
Hikari Power
Tokyo,
Japan
| $1.88M | +$366K | +250 | +20% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $710K | – | – | – |
|
|
VC
3
Vivo Capital
Palo Alto,
California
| $543K | – | – | – |
|
4
Millennium Management
New York
| $43K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $43K | +$51.3K | +35 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $19K | +$22K | +15 | New |
|
7
Parallax Volatility Advisers
San Francisco,
California
| $12K | – | – | – |
|
|
ECM
8
Endurant Capital Management
San Mateo,
California
| – | -$419K | -205 | Closed |
|
|
AAMU
9
Amundi Asset Management US
Boston,
Massachusetts
| – | -$86K | -42 | Closed |
|
|
10
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$38K | -19 | Closed |
|
|
LTFS
11
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$4K | -2 | Closed |
|
AKTX Hedge Fund Activity: Q4 2018 in Review
7 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2018, worth a combined $3.25M — down 38% from $5.25M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AKTX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Hikari Power, adding an estimated $366K. The largest seller was Endurant Capital Management, exiting entirely with an estimated $419K sold.
- 7 institutional investors held Akari Therapeutics (AKTX) as of Q4 2018, down from 10 in Q3 2018.
- Funds reported $3.25M of Akari Therapeutics stock for Q4 2018, down 38% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q4 2018 and 4 closed out, a net change of -2 holders.
- The largest Akari Therapeutics buyer in Q4 2018 was Hikari Power, an estimated $366K added.
- The largest Akari Therapeutics seller in Q4 2018 was Endurant Capital Management, an estimated $419K sold.
Based on aggregated 13F filings for Q4 2018.